Eosinophilic granulomatosis with polyangiitis: A review

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Eosinophilic granulomatosis with polyangiitis (EGPA), previously Churg-Strauss syndrome, is a rare multi-system inflammatory disease.
• EGPA is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) characterized by asthma, eosinophilia, and small-to-medium vessel vasculitis.
• It exhibits unique features distinguishing it from other AAVs, leading to limited research and understanding.

Purpose of the Study:

• To review the pathophysiology, clinical features, diagnosis, management, and prognosis of EGPA.
• To highlight the unmet need for effective, steroid-sparing treatments for EGPA.
• To discuss the evolving management strategies, including novel therapies beyond traditional immunosuppression.

Main Methods:

• Literature review and synthesis of current research on EGPA.
• Analysis of clinical characteristics and diagnostic criteria for EGPA.
• Evaluation of existing and emerging treatment options for EGPA.

Main Results:

• EGPA presents distinct pathophysiology and clinical manifestations compared to other AAVs.
• Current management relies heavily on corticosteroids, with a need for steroid-sparing alternatives.
• Interleukin-5 inhibitors represent a significant advancement in EGPA treatment.

Conclusions:

• EGPA requires tailored management strategies due to its unique disease characteristics.
• Further research is crucial to optimize understanding and treatment of EGPA.
• The development of targeted therapies offers improved prognosis and quality of life for EGPA patients.